Cancer

Firm behind non-invasive cancer tests receives $27m funding

Local genomic medicine company Lucence announced last week that it has received US$20 million (S$27 million) in initial funding after it invented a non-invasive test for late-stage cancer...

Cancer screening startup Lucence raises US$20m in funding led by IHH

GENOMIC medicine firm Lucence Diagnostics on Wednesday announced it has closed a US$20 million Series A funding round led by mainboard-listed IHH Healthcare, one of the world’s largest private...

Singapore-based firm on track to commercialise cancer drug

SCIENTISTS are now a step closer to turning cancer patients' own immune cells (T-cells) against the tumours in their bodies - and possibly finding a cure for the dreaded disease.

Startup creates alternative test for cancer

CURRENT cancer screening methods are invasive and costly. Think of the mammographies, endoscopies, or biopsies that are presently done to detect cancer. Local biotechnology start-up Mirxes Pte Ltd is...